Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Volpara Solutions Announces First 25 Sales and Installations of Volpara®Enterprise™ Software

Volpara Solutions
Posted on: 02 Nov 17
Volpara Solutions Announces First 25 Sales and Installations of Volpara®Enterprise™ Software Saddleback Hospital, John Muir Breast Health, Carol Milgard Breast Center, ProMedica Among First to Adopt Software Designed to Help Breast Imaging Providers Deliver High-Quality, Personalized Breast Screening

PR Newswire

WELLINGTON, New Zealand, Nov. 2, 2017

WELLINGTON, New Zealand, Nov. 2, 2017 /PRNewswire/ -- Volpara Solutions today announced the first 25 sales and installations of its Volpara®Enterprise™ software, which helps breast imaging providers deliver high quality, personalized breast screening. Installations of VolparaEnterprise software have recently been completed at stand-alone breast imaging clinics, radiology practices, community hospitals and academic medical centers across the United States, Canada, Australia and New Zealand.

Saddleback Hospital of Fountain Valley, Calif., John Muir Breast Health Services of Walnut Creek, Calif., Carol Milgard Breast Center of Tacoma, Wash., Calif., ProMedica of Toledo, Ohio, Women's & Breast Imaging clinic of Perth, Western Australia, and Mayfair of Calgary, AB, are among the first sites to adopt VolparaEnterprise software.  

VolparaEnterprise software is the only solution currently available that provides comprehensive assessment of image quality on every mammography or tomosynthesis study, including patient positioning and compression. It provides automated ConstantQuality performance monitoring through dynamic, interactive dashboards that can drive technologist training and quality improvement programs. Additionally, VolparaEnterprise software has been designed to help facilities comply with the FDA's new EQUIP inspection program. 

"VolparaEnterprise software will ensure our patients receive the best quality mammogram possible, drive continuous improvement programs and individual growth, and streamline our compliance with the new FDA EQUIP quality requirements," said Robin Shermis, MD, Medical Director, ProMedica. "In addition, the incorporated VolparaDensity software provides a steadfast means of identifying women who will benefit from adjuvant screening."

VolparaEnterprise software is fully integrated with VolparaDensity software, the most clinically validated 3D Density solution, currently in use in 35 countries. With the massive scalability of by the Microsoft Azure cloud, VolparaEnterprise software enables breast imaging enterprises both large and small to optimize productivity and use resources efficiently through rapid quality control checks, which may help decrease costs through the reduction of retakes, increased employee effectiveness, and an enhanced patient experience.

"The ability of a breast radiologist to detect breast cancer is limited by the quality of the mammogram images they are presented. VolparaEnterprise gives us the ability to monitor the technical quality of every mammogram performed at our breast centers. It is an invaluable tool used to consistently measure image quality and improve technologist performance. Additionally, with objective information rapidly available, we can more accurately assess breast density and identify high risk patients requiring adjuvant screening," said Gary Levine, MD, Medical Director, MemorialCare Breast Centers. 

"Our VolparaEnterprise software is getting a significant amount of interest from breast screening clinics and hospitals because of its benefits as a robust clinical management resource. It helps users optimize productivity, drive quality assurance, which we believe, will improve clinical performance. It is currently the only solution available that provides a comprehensive assessment of image quality on every mammogram, including critical factors like patient positioning and compression, which the FDA has stated are the most common reasons that facilities fail inspections," said Ralph Highnam, PhD, Volpara Chief Scientist and CEO.  "The wide array of quality control features and performance data provided by VolparaEnterprise software are designed to enhance quality and productivity, and help facilities more easily comply with the new EQUIP requirements."

About Volpara Solutions
Founded with the goal of helping radiologists give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Volpara Health Technologies Limited of New Zealand (formerly Matakina Technology). Available in most markets where breast cancer screening is commonplace, VolparaDensity provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis data. VolparaDensity is part of a suite of quantitative breast imaging tools built on the Volpara Solutions algorithm that allows for personalized measurements of density, patient-specific x-ray dose, breast compression, breast positioning and other factors designed to provide critical insight for breast imaging workflow. For more information, visit www.volparasolutions.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/volpara-solutions-announces-first-25-sales-and-installations-of-volparaenterprise-software-300548143.html

SOURCE Volpara Solutions

PR Newswire
www.prnewswire.com

Last updated on: 02/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.